

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY:
ANDEMBRY® (garadacimab-gxii, inhibitor of activated FXII)
BERINERT® (plasma derived C1 esterase inhibitor)
CINRYZE™ (plasma derived C1 esterase inhibitor)
EKTERLY® (sebetralstat, kallikrein inhibitor)
FIRAZYR® (icatibant, bradykinin B2 inhibitor)
HAEGARDA® (C1 esterase inhibitor)
Icatibant Acetate (bradykinin B2 inhibitor)
KALBITOR (ecallantide)
ORLADEYO™ (berotralstat, kallikrein inhibitor)
RUCONEST® (recombinant human C1 esterase inhibitor)
SAJAZIR™ (icatibant, bradykinin B2 inhibitor)
TAKHZYRO™ (lanadelumab-flyo, kallikrein monoclonal antibody)

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

Criteria:

Section A. Acute Attacks of Hereditary Angioedema (HAE):

BERINERT® (plasma derived C1 esterase inhibitor)

EKTERLY (sebetralstat, kallikrein inhibitor)

FIRAZYR® (icatibant, bradykinin B2 receptor antagonist)

Icatibant (bradykinin B2 receptor antagonist)

KALBITOR® (ecallantide, plasma kallikrein inhibitor) – not for self-administration

RUCONEST® (recombinant human C1 esterase inhibitor)

SAJAZIR™ (icatibant, bradykinin B2 receptor antagonist)

- **Criteria for initial therapy:** Berinert (pdC1INH), Ekterly (sebetralstat), icatibant (generic, Firazyr, Sajazir), Kalbitor (ecallantide), or Ruconest (rhC1INH) is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Allergist or Immunologist
 2. Individual's age is consistent with FDA product label for the requested product
 3. Individual has a confirmed diagnosis of recurrent episodes of acute attacks of hereditary angioedema (HAE) that requires therapy
 4. Diagnosis of hereditary angioedema (HAE) is supported by **ONE** of the following:
 - a. Confirmed pathogenic variant in the *SERPING1* gene
 - b. HAE C1 inhibitor (HAE-C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by **BOTH** of the following:
 - i. Two sets C1-inhibitor (C1INH) levels showing either: a protein level below the lower limit of normal or activity/functional level below the lower limit of normal (done at least one month apart)
 - ii. Two sets C4 level below the lower limit of normal (done at least one month apart)
 - c. HAE C1 inhibitor (level and activity/function) & C4 levels are normal (HAE-nl-C1-INH, formerly Type III) and **ONE** of the following:
 - i. Documentation of a positive family history of recurrent angioedema **and** documented lack of efficacy of high-dose antihistamine therapy (i.e., cetirizine at 40 mg/d or the equivalent) for at least 1 month (**or** an interval expected to be associated with 3 or more attacks of angioedema, whichever is longer)
 - ii. Presence of a mutation specific for HAE with normal C1-INH ([see Definitions section](#))
 5. Individual does not have **any** of the following:
 - a. Angioedema episodes from use of angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), or history to suggest an allergic cause
 - b. Angioedema episodes that respond to antihistamines, glucocorticoids, epinephrine, or Xolair (omalizumab)
 - c. Urticaria (hives) or pruritus (itching) with episodes of HAE

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

6. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
7. Documented failure, contraindication per FDA label, intolerance, or is not a candidate for **generic icatibant**
8. **Additional criteria for Kalbitor (ecallantide) only:**
 - a. Kalbitor (ecallantide) will be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and HAE
 - b. Use is contraindicated in an individual with known clinical hypersensitivity to Kalbitor (ecallantide)
10. **Additional criteria for Ekterly (sebetralstat) only:**
 - a. Individual is not using strong CYP3A4 inhibitors ([see Definitions section](#))
 - b. Individual is not using moderate or strong CYP3A4 inducers ([see Definitions section](#))
 - c. Individual does not have severe hepatic impairment (Child-Pugh Class C)
 - d. Individual does not have moderate and severe renal impairment (eGFR <60 mL/min/1.73 m²)
 - e. Individual does not have **ANY** concomitant diagnosis of another form of chronic angioedema such as:
 - i. HAE with normal C1-INH (previously known as HAE type III)
 - ii. Idiopathic angioedema
 - iii. Angioedema associated with urticaria
 - iv. Acquired C1 inhibitor deficiency
 - f. Individual is not using angiotensin converting enzyme inhibitors (ACEIs)
11. Individual will **NOT** be using combination therapy with another agent for the treatment of **acute attacks of angioedema** unless provider submits justification for combination therapy

Initial approval duration: 6 months, for a quantity that is enough for treatment of two attacks with 1 refill

➤ **Criteria for continuation of coverage (renewal request):** Berinert, Ekterly (sebetralstat), icatibant (generic, Firazyr, Sajazir), Kalbitor (ecallantide), or Ruconest is considered **medically necessary** and will be approved when **ALL** of the following criteria are met (**samples are not considered as continuation of therapy**):

1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Allergist or Immunologist
2. Individual has documentation of positive clinical response to therapy defined as **ONE** of the following:
 - a. Achieved and maintains a reduction in the number of acute attacks of HAE
 - b. Achieved and maintains a reduction in the duration of acute attacks of HAE
 - c. Achieved and maintains a reduction in the number of days with acute symptoms
3. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
4. Additional criteria for continuation of **Firazyr (icatibant) and Sajazir (icatibant)**: Individual has failure, contraindication per FDA label, or intolerance, or is not a candidate for equivalent **generic icatibant**

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

5. **Additional criteria for Kalbitor (ecallantide) only:**
 - a. Kalbitor (ecallantide) will be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and HAE
 - b. Use is contraindicated in an individual with known clinical hypersensitivity to Kalbitor (ecallantide)
6. **Additional criteria for Ekterly (sebetralstat) only:**
 - a. Individual is not using strong CYP3A4 inhibitors
 - b. Individual is not using moderate or strong CYP3A4 inducers
 - c. Individual does not have severe hepatic impairment (Child-Pugh Class C)
 - d. Individual does not have moderate and severe renal impairment (eGFR <60 mL/min/1.73 m²)
 - e. Individual does not have **ANY** concomitant diagnosis of another form of chronic angioedema such as:
 - i. HAE with normal C1-INH (previously known as HAE type III)
 - ii. Idiopathic angioedema
 - iii. Angioedema associated with urticaria
 - iv. Acquired C1 inhibitor deficiency
 - f. Individual is not using angiotensin converting enzyme inhibitors (ACEIs)
7. Individual has been adherent with the medication
8. Individual does not have **any** of the following:
 - a. Angioedema episodes from use of angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), or history to suggest an allergic cause
 - b. Angioedema episodes that respond to antihistamines, glucocorticoids, epinephrine, or Xolair (omalizumab)
 - c. Urticaria (hives) or pruritus (itching) with episodes of HAE
9. There is no evidence that the individual has developed any significant unacceptable adverse drug effects from use of the agent that may exclude continued use
10. Individual will **NOT** be using combination therapy with another agent for treatment of **acute attacks of angioedema** unless provider submits justification for combination therapy

Renewal duration: 6 months, for a quantity that is enough for treatment of two attacks with 1 refill

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-Cancer Medications**
2. **Off-Label Use of Cancer Medications**

Section B. Prophylaxis of Attacks of Hereditary Angioedema (HAE): **ANDEMBRY (garadacimab, inhibitor of activated FXII)** **CINRYZE™ (plasma derived C1 esterase inhibitor)** **HAEGARDA® (plasma derived C1 esterase inhibitor)**

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

ORLADEYO™ (berotralstat, kallikrein inhibitor)

TAKHZYRO™ (lanadelumab-flyo, kallikrein monoclonal antibody)

- **Criteria for initial therapy:** Andembry (garadacimab), Cinryze, Haegarda, Orladeyo, or Takhzyro is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Allergist or Immunologist
 2. Individual's age is consistent with FDA product label for the requested product
 3. Individual has frequent or severe attacks of hereditary angioedema (HAE) that requires routine long-term prophylaxis
 4. Diagnosis of hereditary angioedema (HAE) is supported by **ONE** of the following:
 - a. Confirmed pathogenic variant in the *SERPING1* gene
 - b. HAE C1 inhibitor (HAE-C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by **ALL** of the following:
 - i. Two sets C1-inhibitor (C1INH) levels showing either: a protein level below the lower limit of normal or activity/functional level below the lower limit of normal (done at least one month apart)
 - ii. Two sets C4 level below the lower limit of normal (done at least one month apart)
 - c. HAE C1 inhibitor (level and activity/function) & C4 levels are normal (HAE-nl-C1-INH, formerly Type III) and of **ONE** of the following:
 - i. Documentation of a positive family history of recurrent angioedema and documented lack of efficacy of high-dose antihistamine therapy (i.e., cetirizine at 40 mg/d or the equivalent) for at least 1 month (**or** an interval expected to be associated with 3 or more attacks of angioedema, whichever is longer)
 - ii. Presence of a mutation specific for HAE with normal C1-INH ([see Definitions section](#))
 5. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
 6. Individual does not have **any** of the following:
 - a. Angioedema episodes from use of angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), or history to suggest an allergic cause
 - b. Angioedema episodes that respond to antihistamines, glucocorticoids, epinephrine, or Xolair (omalizumab)
 - c. Urticaria (hives) or pruritus (itching) with episodes of HAE
 7. **ONE** of the following:
 - a. Individual with HAE-C1-INH has frequent or severe acute attacks of angioedema and requires long term prophylaxis
 - b. Individual with HAE-nl-C1-INH has frequent or severe acute attacks of angioedema and requires long term prophylaxis and the individual has documented failure, intolerance, contraindication per FDA label, or is not a candidate for **ONE** of the following:
 - i. Oral tranexamic acid

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

- ii. Progesterone-only contraceptives (in premenopausal female)
- iii. Androgen (generally in adult male)

8. **Additional criteria for Orladeyo only:**

- a. Individual does not have end stage renal disease (creatinine clearance of less than 15mL/min or estimated glomerular filtration rate less than 15 mL/min/m² or requiring hemodialysis)
- b. Individual is not on P-gp inducing agents such as rifampin, St. John's Wort, etc

9. Individual will **NOT** be using combination therapy with another agent for **prevention/prophylaxis of attacks** of HAE unless provider submits justification for combination therapy

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Andembry (garadacimab), Cinryze, Haegarda, Orladeyo, or Takhzyro is considered ***medically necessary*** and will be approved when **ALL** of the following criteria are met (**samples are not considered as continuation of therapy**):

1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Allergist or Immunologist
2. Individual has documentation of positive clinical response to therapy defined as **ONE** of the following:
 - a. Achieved and maintains a reduction in the number of HAE attacks
 - b. Achieved and maintains a reduction in the duration of HAE attacks
 - c. Achieved and maintains a reduction in the number of days with symptoms
3. Individual has been adherent with the medication
4. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
5. Individual does not have **any** of the following:
 - a. Angioedema episodes from use of angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), or history to suggest an allergic cause
 - b. Angioedema episodes that respond to antihistamines, glucocorticoids, epinephrine, or Xolair (omalizumab)
 - c. Urticaria (hives) or pruritus (itching) with episodes of HAE
6. **Additional criteria for Orladeyo only:**
 - a. Individual does not have end stage renal disease (creatinine clearance of less than 15mL/min or estimated glomerular filtration rate less than 15 mL/min/m² or requiring hemodialysis)
 - b. Individual is not on P-gp inducing agents such as rifampin, St. John's Wort, etc
 - c. The requested dose is **NOT** greater than 150 mg daily
7. There is no evidence the individual has developed any significant unacceptable adverse drug effects from use of the agent that may exclude continued use

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

8. Individual will **NOT** be using combination therapy with another agent for prevention/prophylaxis of attacks of HAE unless provider submits justification for combination therapy

Renewal duration: 12 months

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-Cancer Medications**
 2. **Off-Label Use of Cancer Medications**
-

Benefit Type:

Pharmacy Benefit:

ANDEMBRY
BERINERT
CINRYZE
EKTERLY
FIRAZYR
HAEGARDA
Icatibant Acetate
ORLADEYO
RUCONEST
SAJAZIR
TAKHZYRO

Medical Benefit:

KALBITOR

Coding:

HCPCS: J1290

Description:

Hereditary angioedema (HAE) is an autosomal dominant disorder that results from C1 esterase inhibitor (C1INH) deficiency. C1INH regulates the activity of the complement component C1, the first step in the classic complement cascade.

HAE is a disease characterized by recurrent episodes of angioedema, **without** urticaria or pruritus, most often affecting the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. People with HAE can develop rapid painful swelling of the hands, feet, limbs, face, intestinal tract, or airway. Acute attacks of swelling can occur spontaneously, or can be triggered by stress, surgery, medical or dental procedures, or infection. The swelling is often self-limited and resolves in two to five days without treatment, however laryngeal involvement may cause fatal asphyxiation.

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

The swelling (i.e., angioedema) that occurs in HAE results from excessive production of bradykinin, a potent mediator of vasodilation. Bradykinin also has important vascular permeability-enhancing effects. During episodes of angioedema individuals with HAE have plasma bradykinin levels shown to be substantially higher than normal

HAE is caused by low levels or inadequate function of a plasma protein called C1-esterase inhibitor (C1INH) that is involved in regulating how some portions of the immune system and blood clotting pathways work. The absence or dysfunction of C1INH leads to an increase in bradykinin production. Bradykinin dilates blood vessels which is responsible for the symptoms of HAE.

The angioedema of HAE mediated by bradykinin does not respond to epinephrine, antihistamines, or glucocorticoids.

Therapeutic approaches for HAE include both “on-demand” treatments given at the onset of symptoms to abolish angioedema attacks as well as prophylactic treatment used to prevent or minimize attacks. All individuals require a readily available on-demand treatment to terminate unpredictable angioedema episodes. Short-term prophylaxis is use of medication given before a known trigger such as specific medical or dental procedures. In contrast, long-term prophylaxis is given to decrease the number and length of attacks. An integral part of treatment is trigger avoidance, if possible.

Therapies that are minimally effective or have no benefit at all in the treatment of acute angioedema in HAE include androgens, tranexamic acid, and treatments for allergic (histaminergic) angioedema such as epinephrine. Glucocorticoids and antihistamines are NOT effective for angioedema associated with disorders of C1INH and should not be given once the diagnosis of a C1INH disorder has been made.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Comparison of complement studies in angioedema disorders

Angioedema disorder	C4*	C1-INH level	C1-INH function/activity	C1q	Other tests
HAE with C1-INH deficiency type I (HAE-C1-INH type I)	Low	Low	Low (usually < 50% of normal)	Normal	Genetic testing (not needed for Dx)
HAE with C1INH deficiency type II (HAE-C1-INH type II)	Low	Normal or elevated	Low (usually < 50% of normal)	Normal	Genetic testing (not needed for Dx)
Hereditary Angioedema Type III (HAE-III):					
HAE with coagulation factor XII gene mutations (HAE-FXII)	Normal	Normal	Normal	Normal	Mutations in gene for factor XII
HAE with angiotensinogen-converting enzyme (ACE) gene mutations (HAE-ANGPT1)	Normal	Normal	Normal	Normal	Mutations in gene for angiotensinogen-converting enzyme

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

HAE with plasminogen gene mutations (HAE-PLG)	Normal	Normal	Normal	Normal	Mutations in gene for plasminogen
HAE with kininogen-1 gene mutations (HAE-KNG1)	Normal	Normal	Normal	Normal	Mutations in gene for kininogen-1
HAE with myoferlin (HAE-myoferlin)	Normal	Normal	Normal	Normal	Mutation in the MYOF gene
HAE with heparan sulfate-glucosamine 3-O-sulfotransferase 6	Normal	Normal	Normal	Normal	Mutation in the gene HS3ST6
HAE of unknown origin (HAE-U)	Normal	Normal	Normal	Normal	Unknown
Acquired angioedema with C1-INH deficiency (AAE-C1-INH)	Low	Normal or low	Low (usually < 50% of normal)	Normal or low [†]	Anti-C1-INH antibodies (not needed for diagnosis)
Idiopathic acquired angioedema (histaminergic or non-histaminergic) (AAE-IH or AAE-InH)	Normal	Normal	Normal	Normal	
ACE inhibitor-associated angioedema (AAE-ACEI)	Normal	Normal	Normal	Normal	
<p>* In HAE-C1-INH types I and II, C4 is always low during an attack (with one published exception) and are chronically low in the majority of patients.</p> <p>[†] There are rare forms of acquired angioedema in which C1q levels are normal.</p>					

Medications used for treating individuals with HAE:

Drug	Age	Route	Self-Administer	Dose	How supplied
On-demand medications for acute attacks HAE					
PLASMA DERIVED C1 ESTERASE INHIBITOR (pdC1INH): Berinert	5	IV	Yes	20 IU per kg A second dose can be given 4 hours after the initial dose	500 IU single-use vial
RECOMBINANT C1 ESTERASE INHIBITOR (rhC1INH): Ruconest	13	IV	Yes	< 84 kg: 50 IU per kg ≥ 84 kg: 4200 units (2 vials) Max 4200 IU per dose No more than two doses in 24 hours, however a second dose is rarely needed	2100 IU single-use vial
BRADYKININ B2 RECEPTOR ANTAGONIST: Firazyr (icatibant) Icatibant Sajazir (icatibant)	18	SQ	Yes	30 mg injected to the abdominal area Additional doses can be given after 6 hours. Max of three doses in 24 hours	Single-dose, single-use, prefilled syringe with 30 mg per syringe packaged as single carton with one syringe or pack of three cartons each with one syringe

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

KALLIKREIN INHIBITOR: Ekterly (sebetralstat)	12	PO	Yes	One dose of 600 mg (2 tabs) taken orally at the earliest recognition of an HAE attack. A second dose of 600 mg (2 tabs) may be taken 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur. Maximum Dosage: 1,200 mg in any 24-hour period	300 mg tablets
KALLIKREIN INHIBITOR: Kalbitor (ecallantide)	12	SQ	No	30 mg injected (3 doses of 10 mg (1 mL) each) given at three separate sites. A second dose can be given within 24 hours after the initial dose	Three 10 mg/mL single-use vials packaged in a carton
Prophylaxis of HAE					
ACTIVATED FACTOR XII (FXIIA) INHIBITOR MONOCLONAL ANTIBODY: Andembry (garadacimab-gxii)	12	SQ	Yes	Initial loading dose of 400 mg (two 200 mg injections) subcutaneously followed by maintenance dosage of 200 mg once monthly	200 mg/1.2 mL solution in single-dose prefilled autoinjector 200 mg/1.2 mL (167 mg/mL) solution in single-dose prefilled syringe with needle safety device
PLASMA DERIVED C1 ESTERASE INHIBITOR (pdC1INH): Cinryze	6	IV	Yes	<u>12 years and older:</u> 1,000 units every 3 or 4 days Up to 2,000 units (80 U/kg) every 3 or 4 days <u>6-11 years of age:</u> 500 units every 3 or 4 days Up to 1,000 units every 3 or 4 days	500 IU single-use vial
PLASMA DERIVED C1 ESTERASE INHIBITOR (pdC1INH): Haegarda	6	SQ	Yes	60 IU per kg twice weekly (every 3 or 4 days)	2000 or 3000 IU single-use vials
ORAL KALLIKREIN INHIBITOR: Orladeyo (berotralstat)	12	PO	Yes	150 mg orally once daily or 110 mg orally once daily in patients with moderate or severe hepatic impairment; persistent GI events; and certain drug-drug interactions Additional doses or doses higher than 150 mg once daily are <u>not recommended</u> due to QT prolongation	110 mg, 150 mg capsule

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

KALLIKREIN INHIBITOR MONOCLONAL ANTIBODY: Takhzyro (lanadelumab-flyo)	2	SQ	Yes	<u>12 years and older:</u> 300 mg every 2 or 4 weeks <u>6 to less than 12 years of age:</u> 150 mg every 2 or 4 weeks <u>2 to less than 6 years of age:</u> 150 mg every 4 weeks	300 mg single-use vial 300 mg single-use syringe 150 mg single-use syringe
ANDROGENS: Danazol	16	PO	Yes	Approved for adults: 200 mg/d PO (100 mg every 3 d to 600 mg/d) Off-label for pediatric individuals: 50 mg/d PO (50 mg/week to 200 mg/d)	50 mg, 10 mg, 200 mg capsules
ANTIFIBRINOLYTICS: Tranexamic Acid	12	PO	Yes	Off-label for adult: 1 g PO bid (0.25 g bid to 1.5 g tid) Off-label for pediatric individuals: 20 mg/kg PO bid (10 mg/kg bid to 25 mg/kg tid)	650 mg tablets

Treatments used for acute episodes of hereditary angioedema (HAE):

	Laryngeal attack	Abdominal attack	Cutaneous attack	
			Extremities, trunk	Face, neck
C1INH concentrate (plasma derived or recombinant) given intravenously	Yes	Yes	Yes, unless swelling is extensively mild and not causing disability	Yes
Kalbitor (ecallantide)	Yes	Yes	Yes, unless extensively mild	Yes
Icatibant	Yes	Yes	Yes, unless extensively mild	Yes
Plasma (solvent / detergent treated or fresh frozen)	Yes, if first line therapies are not available	Yes, if first line therapies are not available	Yes, if severe and first line therapies are not available	Yes
Intubation, transfer to ICU	Yes, consider early intubation if above agents are not available	Not applicable	Not applicable	May be necessary if attack spreads to involve upper airway
Wait and see for spontaneous resolution	Not sufficient	Not recommended unless symptoms are mild and first line therapies are not available	Acceptable if mild	Not sufficient because angioedema can spread to involve airway

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

Choices of prophylactic agent for hereditary angioedema (HAE) in specific patient groups

Patient population	Preferred agents	Alternate agents	Agents to avoid	Other notes
Pre-pubertal children (male and female)	Plasma-derived C1-INH* (Cinryze, Haegarda)	Tranexamic acid (less effective but may be sufficient for mild disease)	Androgens¶	Berotrastat not studied or approved for children under 12 years of age
Adult women not considering pregnancy and post-pubertal girls	Plasma-derived C1-INH* (Cinryze, Haegarda) Lanadelumab (Takhzyro) Berotrastat (Orladeyo)	Tranexamic acid (less effective but may be sufficient for mild disease)	Androgens (multiple side effects and virilization)	
Adult men and post-pubertal boys	Plasma-derived C1-INH* (Cinryze, Haegarda) Lanadelumab Berotrastat	Tranexamic acid (less effective but may be sufficient for mild disease) Androgens (multiple side effects but virilization less of an issue for men)		
Pregnant and lactating women	Plasma-derived C1-INH* (Cinryze, Haegarda) – have the most safety data	Tranexamic acid (less effective but history of safe use)	Androgens Δ	Lanadelumab and berotrastat not recommended because they have not been studied in pregnancy

The choice of which long-term prophylactic agent to use is influenced both by patient characteristics (age, gender, pregnancy/lactation), as shown in the table, as well as regulatory requirements in different countries.

* Plasma-derived C1-INH can be given subcutaneously or intravenously. Subcutaneous is more convenient and appears to be more effective based on preliminary evidence.

¶ Androgens are contraindicated in pre-pubertal children because they can cause premature closure of the growth plates.

Δ Androgens are avoided in pregnancy because they can result in virilization of female fetuses, although if a woman with HAE is carrying a male fetus, androgens have been successfully used with supervision by an endocrinologist.

CYP3A4 Inhibitors: (not a complete listing)

boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole

CYP3A4 Inducers: (not a complete listing)

apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wo

Resources:

Andemby (garadacimab-gxii) product information, revised by CSL Behring 06-2025, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed July 18, 2025.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

Ekerly (sebetralstat) product information, revised by KalVista Pharmaceuticals, Ltd. 07-2025, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed July 18, 2025.

Beriner (C1 esterase inhibitor, human) product information, revised by CSL Behring GmbH 09-2021, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Cinryze (C1 esterase inhibitor, human) product information, revised by Takeda Pharmaceuticals America, Inc. 02-2023, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Haegarda (C1 esterase inhibitor, human) product information, revised by CSL Behring GmbH 01-2022, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Ruconest (C1 esterase inhibitor, recombinant) product information, revised by Pharming Healthcare, Inc. 04-2020, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Firazyr (icatibant) product information, revised by Takeda Pharmaceuticals America, Inc. 01-2024, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Sajazir (icatibant) product information, revised by Cycle Pharmaceuticals Ltd-UK. 02-2024, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Icatibant product information, revised by Teva Pharmaceutical USA, Inc. 10-2022, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Kalbitor (ecallantide) product information, revised by Takeda Pharmaceuticals America, Inc. 11-2021, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Orladeyo (berotralstat) capsule product information, revised by BioCryst Pharmaceuticals, Inc. 11-2023, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Takhzyro (lanadelumab-flyo) product information, revised by Takeda Pharmaceuticals America. 02-2023, at DailyMed <http://dailymed.nlm.nih.gov>. Accessed September 18, 2024.

Zuraw B, Farkas H. Hereditary angioedema (due to C1 inhibitor deficiency): Pathogenesis and diagnosis. In: UpToDate, Saini S, Feldweg AM (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Literature current through July 2024. Topic last updated February 08, 2022. Accessed September 18, 2024.

Zuraw B, Farkas H. Hereditary angioedema (due to C1 inhibitor deficiency): Epidemiology, clinical manifestations, exacerbating factors, and prognosis. In: UpToDate, Saini S, Feldweg AM (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Literature current through July 2024. Topic last updated July 12, 2024. Accessed September 18, 2024.

Zuraw B, Bork K. Hereditary angioedema with normal C1 inhibitor. In: UpToDate, Saini S, Feldweg AM (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Literature current through July 2024. Topic last updated June 22, 2024. Accessed September 18, 2024.

Zuraw B, Farkas H. Hereditary angioedema (due to C1 inhibitor deficiency): Acute treatment of angioedema attacks. In: UpToDate, Saini S, Feldweg AM (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Literature current through July 2024. Topic last updated August 06, 2024. Accessed September 18, 2024.

Zuraw B, Farkas H. Hereditary angioedema: Short-term prophylaxis before procedures or stressful events to prevent angioedema episodes. In: UpToDate, Saini S, Feldweg AM (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Literature current through July 2024. Topic last updated June 29, 2023. Accessed September 18, 2024.

Zuraw B, Farkas H. Hereditary angioedema (due to C1 inhibitor deficiency): General care and long-term prophylaxis. In: UpToDate, Saini S, Feldweg AM (Eds), UpToDate, Waltham MA.: UpToDate Inc. <http://uptodate.com>. Literature current through July 2024. Topic last updated August 06, 2024. Accessed September 18, 2024.

Busse PJ, Christiansen SC, Riedl MA, et al: US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract 2021 Jan; 9(1):132-150. Accessed January 20, 2021. Re-evaluated August 19, 2024.

ORIGINAL EFFECTIVE DATE: 04/01/2019 | ARCHIVE DATE: | LAST REVIEW DATE: 11/21/2024 | LAST CRITERIA REVISION DATE: 08/21/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

HEREDITARY ANGIOEDEMA MEDICATION THERAPY

Maurer M, Magerl M, Betschel S, et al.: The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. World Allergy Organization Journal 2022 March; 15(3):100627 <http://doi.org/10.1016/j.waojou.2022.100627>. Accessed October 10, 2023. Re-evaluated August 19, 2024.

Betschel S, Badiou J, Binkley K, et al.: The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol 2019; 15:72 <https://doi.org/10.1186/s13223-019-0376-8>. Accessed October 10, 2023. Re-evaluated August 19, 2024.

Beard N, Frese M, Smertina E, et al: Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database of Systematic Reviews 2022, Issue 11. Art. No.: CD013403. DOI: 10.1002/14651858.CD013403.pub2. Accessed July 18, 2025.

ClinicalTrials.gov Bethesda (MD): National Library of Medicine (US). Identifier NCT04656418: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema. Available from: <http://clinicaltrials.gov>. Last update posted June 29, 2023. Last verified June 2023. Accessed July 18, 2025.

ClinicalTrials.gov Bethesda (MD): National Library of Medicine (US). Identifier NCT05259917: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II. Available from: <http://clinicaltrials.gov>. Last update posted May 02, 2025. Last verified April 2025. Accessed July 18, 2025.

Riedl MA, Farkas H, Aygoren-Pursun E, et al.: Oral Sebetrastat for On-Demand Treatment of Hereditary Angioedema Attacks. NEJM 2024 Jul 4;391(1):32-43. doi: 10.1056/NEJMoa2314192. Accessed July 18, 2025.